SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Ma, L ^a   Maruwge, W ^a   Strambi, A ^a   Arcy, P D ^a   Pellegrini, P ^a   Kis, L ^a   De Milito, A ^a   Lain, S ^a   Brodin, B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; SIRTUIN 1; SIRTUIN 2; SIRTUIN INHIBITOR; SMALL INTERFERING RNA; TENOVIN 6; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CASPASE 3; CASPASE 7; CYCLIN DEPENDENT KINASE INHIBITOR 1A; LIGHT CHAIN 3, HUMAN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; NICOTINAMIDE; PROTEIN P53; SIRT1 PROTEIN, HUMAN; SIRT2 PROTEIN, HUMAN; TENOVIN-6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER GROWTH; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; MOUSE; NONHUMAN; PEDIATRIC SOFT TISSUE SARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA CELL LINE; SARCOMA CELL LINE; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA CELL; ACETYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; CHILD; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; RHABDOMYOSARCOMA; SARCOMA; SCID MOUSE; SYNOVIAL SARCOMA; TUMOR CELL LINE;

MAMMALIA; SACCHAROMYCETALES;

ACETYLATION; ANIMALS; AUTOPHAGY; BENZAMIDES; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE, SCID; MICROTUBULE-ASSOCIATED PROTEINS; NIACINAMIDE; RHABDOMYOSARCOMA; RNA, MESSENGER; RNA, SMALL INTERFERING; SARCOMA; SARCOMA, SYNOVIAL; SIRTUIN 1; SIRTUIN 2; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928011364     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.385     Document Type: Article

References (33)

1. Vaquero A. The conserved role of sirtuins in chromatin regulation. Int J Dev Biol 2009; 53:303-322.
2. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Gene Dev 1999; 13:2570-2580.
3. North BJ, Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol 2004; 5: 224.
4. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-148.
5. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al. hSIR2(SIRT1) functoins as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-159.
6. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13: 454-463.
7. Yuan H, Su L, Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 2013; 6: 1399-1416.
8. Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM et al. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med 2007; 39: 8-13.
9. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14:312-323.
10. Hiratsuka M. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003; 309:558-566.
11. D'Arcy P, Maruwge W, Ryan BA, Brodin B. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability. Mol Cancer Res 2008; 6: 127-138.
12. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD et al. Frequency and Diversity of p53 Mutations in Childhood Rhabdomyosarcoma. Cncer Res 1992; 52:2243-2247.
13. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009; 41: 366-371.
14. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011; 42: 204-213.
15. Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 2009; 2009: 3823-3832.
16. Dickson BC, Riddle ND, Brooks JS, Pasha TL, Zhang PJ. Sirtuin 1 (SIRT1): a potential immunohistochemical marker and therapeutic target in soft tissue neoplasms with myoid differentiation. Hum Pathol 2013; 44: 1125-1130.
17. Nihal M, Ahmad N, Wood GS. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle 2014; 13: 632-640.
18. Wilking MJ, Singh C, Nihal M, Zhong W, Ahmad N. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys 2014; pii: S0003-9861: 00124-00126. epub ahead of print; doi:10.1016/j.abb.2014.04.001.
19. Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008; 32:1523-1523.
20. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al. hSIR2SIRT1 functions as an NAD+-dependent p53 deacetylase. Cell 2001; 107: 149-159.
21. Groves MJ, Johnson CE, James J, Prescott AR, Cunningham J, Haydock S et al. p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia. Br J Cancer 2013; 109: 2434-2444.
22. Hirai S, Endo S, Saito R, Hirose M, Ueno T, Suzuki H et al. Antitumor effects of a Sirtuin inhibitor, Tenovin-6, against gastric cancer cells via death receptor 5 up-regulation. PLoS One 2014; 9.
23. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007; 39: 1367-1374.
24. McCarthy AR, Sachweh MC, Higgins M, Campbell J, Drummond CJ, van Leeuwen IM et al. Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner. Mol Cancer Ther 2013; 12: 352-360.
25. Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol 2010; 12:665-675.
26. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA 2008; 105: 3374-3379.
27. Hwang JW, Chung S, Sundar IK, Yao H, Arunachalam G, McBurney MW et al. Cigarette smoke-induced autophagy is regulated by SIRT1-PARP-1-dependent mechanism: implication in pathogenesis of COPD. Arch Biochem Biophys 2010; 500: 203-209.
28. Takeda-Watanabe A, Kitada M, Kanasaki K, Koya D. SIRT1 inactivation induces inflammation through the dysregulation of autophagy in human THP-1 cells. Biochem Biophys Res Commun 2012; 427: 191-196.
29. Tang FNaBL, Sirtuins' modulation of autophagy. J Cell Physiol 2013; 228: 2262-2270.
30. Crighton D, Wilkinson S, Ryan KM. DRAM links autophagy to p53 and programmed cell death. Autophagy 2007; 3: 72-74.
31. Kenzelmann Broz D, Attardi LD. TRP53 activates a global autophagy program to promote tumor suppression. Autophagy 2013; 9: 1440-1442.
32. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012; 21: 266-281.
33. Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 2007; 3: 452-460.